---
title: "Genmab rises on upbeat 2025 sales forecast"
date: "2025-02-13 03:05:59"
summary: "** U.S.-listed shares of Denmark-based drugmaker Genmab , up 1.9% to $19.24 ** Company, which develops cancer treatments, sees 2025 sales to be in the range of $3.3 billion to $3.7 billion, banking on strong demand for its blood cancer treatment Darzalex** Analysts were expecting revenue of $3.56 billion on..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

\*\* U.S.-listed shares of Denmark-based drugmaker Genmab , up 1.9% to $19.24

\*\* Company, which develops cancer treatments, [sees](https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250212:nGNX4rq3NV&default-theme=true) 2025 sales to be in the range of $3.3 billion to $3.7 billion, banking on strong demand for its blood cancer treatment Darzalex

\*\* Analysts were expecting revenue of $3.56 billion on average for 2025 â€” LSEG

\*\* Genmab partnered with Johnson & Johnson for Darzalex

\*\* Partner JNJ reported full-year sales of Darzalex rose 20.6% to $11.67 billion in 2024

\*\* Expects 2025 operating expenses to be in the range of $2.1 billion to $2.2 billion due to ongoing late-stage studies of cancer treatments and potential planned launches

\*\* In the last 12 months, stock has fallen 31.1%

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3P31L1:0-genmab-rises-on-upbeat-2025-sales-forecast/)
